Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK

INTRODUCTION: Head and neck cancer is the eighth most common cancer in the UK. Current standard of care treatment for patients with recurrent/metastatic squamous cell head and neck carcinoma (HNSCC) is platinum-based chemotherapy combined with the anti-epidermal growth factor receptor (anti-EGFR) mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Kenrick, Metcalf, Rob, Sacco, Joseph, Kong, Anthony, Wheeler, Graham, Forsyth, Sharon, Bhat, Reshma, Ward, Joseph, Ensell, Leah, Lowe, Helen, Spanswick, Victoria, Hartley, John, White, Laura, Lloyd-Dehler, Elizabeth, Forster, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685941/
https://www.ncbi.nlm.nih.gov/pubmed/38011968
http://dx.doi.org/10.1136/bmjopen-2022-070391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685941/
https://www.ncbi.nlm.nih.gov/pubmed/38011968
http://dx.doi.org/10.1136/bmjopen-2022-070391

Ejemplares similares